HBL - Hadasit Bio-Holdings Ltd Stock price
Equities
HDST-M
IL0010954050
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
54.30 ILa | -10.54% | -10.54% | -58.10% |
Sales 2022 * | - | Sales 2023 * | - | Capitalization | 14.37 M 3.88 M 1,437 M |
---|---|---|---|---|---|
Net income 2022 | -31.00 M -8.36 M -3,100 M | Net income 2023 * | - | EV / Sales 2022 | - |
Net cash position 2022 | 12.93 M 3.49 M 1,293 M | Net cash position 2023 * | - 0 0 | EV / Sales 2023 * | - |
P/E ratio 2022 | -0,46x | P/E ratio 2023 * | Employees | 2 | |
Yield 2022 | - | Yield 2023 * |
-
| Free-Float | 25.00% |
More Fundamentals
* Assessed data
More news
1 day | -10.54% | ||
1 week | -10.54% | ||
1 month | -20.50% | ||
3 months | -39.19% | ||
6 months | -61.32% | ||
Current year | -58.10% |
1 week
48.40
48.40

1 month
48.40
63.70

Current year
40.10
210.00

1 year
40.10
210.00

3 years
40.10
1 153.00

5 years
40.10
1 180.00

10 years
40.10
1 430.00

Managers | Title | Age | Since |
---|---|---|---|
Yoram Azulai
CEO | Chief Executive Officer | 62 | 2015 |
Tamar Raz
CHM | Chairman | 60 | 2014 |
Doron Cohen
AUD | Comptroller/Controller/Auditor | 53 | 2015 |
Members of the board | Title | Age | Since |
---|---|---|---|
Doron Nevo
BRD | Director/Board Member | 68 | 2018 |
Erez Meltzer
BRD | Director/Board Member | 66 | 2016 |
Orit Stav
BRD | Director/Board Member | 52 | 2017 |
Date | Price | Change | Volume |
---|
Delayed Quote TEL AVIV STOCK EXCHANGE, November 30, 2023 at 10:24 am EST
More quotes
HBL Hadasit Bio Holdings Ltd (Hadasit) is an investment company, a subsidiary of Hadassah Medical Organization (HMO). The Company's subsidiaries enable research and development and promote intellectual property (IP) to the medical and biotechnological industries. The Company together with its strategic partners, has established a number of start-up companies, and is assigned to commercialize that IP either through granting a product license to biotechnological or pharmaceutical companies or via the creation of a subsidiary which operates in the premise of HMO. Hadasit is equipped with resources and capabilities required for composing and conducting the pre-clinical services and clinical studies, establishing start-up companies, offering product licensing and providing international consulting services. The Company's framework serves to address investment in early-stage biotechnological star-ups, by distributing both risk and success amongst a number of companies.
1st Jan change | Capi. | |
---|---|---|
-58.10% | 2 M $ | |
+65.53% | 40 132 M $ | |
+5.87% | 39 586 M $ | |
-55.56% | 30 438 M $ | |
-26.11% | 28 571 M $ | |
+38.66% | 22 175 M $ | |
-27.87% | 21 511 M $ | |
+1.62% | 17 412 M $ | |
-13.43% | 11 313 M $ | |
-7.44% | 10 346 M $ |